MACROGENICS, INC. Increase Decrease In Operating Lease Liability
MACROGENICS, INC. (MGNX) reported Increase Decrease In Operating Lease Liability of -$513.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-14
- MACROGENICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$261.00K.
- MACROGENICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$252.00K, a 5140.00% decline year-over-year.
- MACROGENICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$238.00K, a 666.67% decline year-over-year.
- MACROGENICS, INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$219.00K, a 586.67% decline year-over-year.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month |
|---|---|---|---|
| 2026-06-30 | -$261.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$513.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$252.00K 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | -$238.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$457.00K derived: sum of 2 quarters · filed 2026-08-14 | -$452.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$219.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$214.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $87.00K derived: sum of 2 quarters · filed 2025-11-12 | $128.00K 10-Q · filed 2025-11-12 |
| 2024-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $86.00K 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $41.00K 10-Q · filed 2025-05-13 | ||
| 2023-09-30 | -$210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$439.00K derived: sum of 2 quarters · filed 2024-11-05 | -$723.00K 10-Q · filed 2024-11-05 |
| 2023-06-30 | -$229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$513.00K 10-Q · filed 2024-08-06 | |
| 2023-03-31 | -$284.00K 10-Q · filed 2024-05-09 | ||
| 2022-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$2.33M derived: sum of 2 quarters · filed 2023-11-06 | -$3.45M 10-Q · filed 2023-11-06 |
| 2022-06-30 | -$1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.26M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | -$1.12M 10-Q · filed 2023-05-09 | ||
| 2021-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.02M derived: sum of 2 quarters · filed 2022-11-03 | -$2.70M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$990.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$1.67M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | -$683.00K 10-Q · filed 2022-05-03 | ||
| 2020-09-30 | -$2.11M 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |